Denmark's BioPorto Q4 revenue rises on NGAL sales

BioPorto A/S

05/02/2026 20:10

Overview

Denmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL sales

Company's FY 2025 revenue grew 11%, within guidance range of DKK 40-45 mln

Adjusted EBITDA loss for FY 2025 was within guidance, estimated at app. DKK 77 mln

Outlook

BioPorto targets 2026 total revenue of DKK 48-58 mln, up 20-45%

Company expects 2026 NGAL revenue to grow 20-50%

BioPorto forecasts 2026 adjusted EBITDA loss of DKK 50-60 mln, a 22-35% decrease

Result Drivers

NGAL SALES - Strong Q4 revenue growth driven by NGAL sales, particularly in the U.S. and strategic distributors

STRATEGIC DISTRIBUTORS - Revenue boost from large bulk order to strategic distributor in Q4

U.S. MARKET ADOPTION - Increased NGAL RUO sales in the U.S. contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
DKK 11.6 mln
Q4 Adjusted EBITDA
DKK 13.7 mln


Press Release: ID:nGNE8ddzFG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)